Tarsons Products Ltd Q1 FY2027 Concall Summary

Key Takeaways

• Demand recovery is real, but margin pain is acute: Revenue grew 15%+ YoY with domestic up 17% and exports up 29%, yet gross margin fell to 67.1% as raw material costs spiked 25–50% and price hikes covered only a fraction of the hit.
• Growth is coming from the old portfolio, not the new capex: Q1 growth was driven predominantly by existing products, leaving significant headroom as Panchla and Amta ramp up, but also meaning the new facilities are currently a cost drag, not a revenue driver.
• FY27 is a margin reset year by design: Profit will stay moderate as depreciation and interest costs peak, with full-year depreciation guided at ₹105–110 crores and interest at ~₹20 crores, before operating leverage kicks in from FY28.
• Export recovery is encouraging but fragile: The 29% export rebound benefited from shipment timing and buyer-nominated logistics, and management explicitly warns a bad export quarter could occur any quarter without reflecting business performance.
• What to watch next quarter: Whether raw material volatility stabilizes enough to hold margins at Q1 levels, whether the remaining facilities commission on schedule in Q2, and whether the 15% FY27 growth target stays intact as new products begin contributing.

Demand Environment

• Domestic momentum: Sales grew 17% YoY on improving demand conditions, with management saying the domestic market is "almost there" to late single digits, the traditional pre-COVID growth rate. Customer inquiries showed a notable uptick during the quarter.
• Export recovery: Export business from India grew 29% in Q1, recovering from disruption caused by West Asia geopolitical tensions and U.S. tariff uncertainty. Inquiry levels are translating into healthy order conversions.
• Shipment timing caveat: Q1 export growth had a "huge benefit of shipments" because shipment timing is beyond company control, with many shipments nominated by buyers and vessel availability affected by the West Asia crisis.
• Trade fair payoff: Ongoing participation in international trade fairs is enhancing visibility and enabling engagement with new customers and markets, with benefits increasingly translating into inquiries, customer additions, and order wins.
• White labeling opportunity: Management sees encouraging opportunities in white labeling, expected to be a key growth driver in export business going forward, and it is included in the 15% growth expectation for export markets.

Sehgal: "We could have a bad quarter for exports in the next quarter or the quarter after that or any of the quarters in the future and that could mean nothing to our business performance in that quarter."

Margin Pressure & Raw Material Volatility

• Input cost spike: Key raw material costs rose 25–50% over recent months, with polymer prices the primary driver of the standalone gross margin decline to 67.1%.
• Price increases insufficient: Partial price increases were implemented domestically, but international price hikes were close to zero, with management relying on rupee depreciation instead. The total price increase across the business was "very marginal" relative to the cost impact.
• Volatility is the new normal: Input costs peaked about six weeks before the call, dipped sharply over ten days after a peace agreement, then moved up sharply again over the last two weeks. Management tracks prices week-on-week and sees no stability at this point.
• External, not internal: Management is explicit that margin erosion is driven entirely by external environment factors, not internal operational metrics. The pure reason for gross margin decline is higher input costs and inability to pass on full price increases.
• FY27 margin outlook: Margins are expected to look similar to Q1 levels for now, with a big difference possible only if input costs change drastically in either direction over the remaining ~7 months.
• International margin deferral: The current focus is growing base and market share internationally, with margin improvement deferred to when the market is more stable and operational leverage can be applied.

Sehgal: "The pure reason for gross margin going down is higher input costs and higher purchase price of raw materials and inability to pass on the entire price increase to customers."

Capacity Ramp-Up & New Facilities

• Commissioning status: A substantial part of planned CAPEX is already commissioned and operational, with trial runs underway across select product lines. Remaining facilities are expected to be fully commissioned during Q2, with revenue contribution beginning from the second half.
• Current revenue contribution: Both Panchla and Amta facilities contributed revenue in Q1, but most Panchla revenue came from existing products or capacity expansions that moved there, not from new product categories.
• Cost drag today: EBITDA is impacted by operating costs associated with recently commissioned facilities, with ramp-ups and revenue contribution scaling progressively over coming years.
• Depreciation peak: Full-year depreciation is expected at approximately ₹105–110 crores, which management says will be the peak year. Interest cost runs at ~₹20 crores per year through FY27, then declines in FY28.
• No major new capex: No major CAPEX is planned for this year, only maintenance CAPEX not expected to exceed ₹20-odd crores per year, with tough years possibly reaching ₹25 crores. Pending CAPEX (advances plus CWIP) will be completed within Q2 or Q3 FY27.
• FY28 inflection: Benefits of investments are expected to become increasingly visible from FY28 onwards, supported by better fixed cost absorption and operating leverage as production ramps up and customer approvals progress.

Growth Strategy & New Products

• Existing portfolio headroom: Q1 growth was driven predominantly by the existing product portfolio, leaving significant headroom as expanded capacities and new products ramp up.
• Cell culture entry: Management plans to get deep into the cell culture market over the next 2–3 years and hold meaningful share in India. R&D, QC, and research cell culture products scale faster, while production and bioprocessing products scale slower.
• Biopharma pivot: A strong pivot into specialized biopharmaceutical products is planned over the next 2–3 years to gain meaningful share.
• Benchtop equipment: The company plans to ramp up benchtop equipment after cell culture and biopharma, leveraging its distribution network with low CAPEX compared to plastics.
• New product revenue target: The entire new portfolio, including cell culture, is expected to generate approximately ₹65–70 crores in FY28.
• Bioprocess containers: Media bottles and roller bottles launched last year are fully commercialized and selling in the market, though scaling into customer SOPs as an alternate or secondary supplier is a time-taking process.
• Growth ambition: Management believes the industry position is the "strongest ever in the last 4 to 5 years" and that growth should be at least 15% or more given larger facilities, a stronger company, a larger product line, and new products.

Sehgal: "We would like to grow very, very aggressively, but not over aggressively because sometimes growth, which beyond a certain point, sometimes it is not very, very sustainable as well."

International Business & Nerbe

• German subsidiary resilience: Nerbe delivered revenue growth of approximately 6% YoY in constant currency terms, with the operating environment remaining challenging but the business demonstrating encouraging resilience.
• Cross-sell opportunity: Management sees considerable growth runway through deeper integration and synergies between Nerbe and Tarsons, leveraging Nerbe's established network and customer relationships to cross-sell Tarsons-manufactured products.
• Geographic expansion: Nerbe has tremendous growth opportunities to expand geographical presence outside Germany, expand its product portfolio with Tarsons offerings, and add backward manufacturing for Tarsons.
• Nerbe sales team: No significant increase in headcount over the last 1–1.5 years; upgrades came from replacing people with more experienced industry hires, improving quality not quantity.
• International team structure: The international team is currently based out of India, with local hiring in key geographies planned as scale increases. A key senior-level sales hire in the SMB position has been made, with teams being built below him domestically and in certain key geographies.
• US market: Inquiries are increasing with tariffs at 10%, and business looks promising if the environment remains conducive. Management says logistics, transportation, and input costs are major hurdles, not tariffs.
• Global competition: Management acknowledges global competition was always present pre-COVID and will continue, but believes the company is well-positioned to find a spot in that market.

Sehgal: "Our own endeavor at this point is to increase and build our base internationally and then, at a more opportune time when the market is more stable, we could find ways on how we can operationally leverage ourselves to improve our margins."

Financial Position & Cash Generation

• Cash profit strength: Cash profit grew 18% YoY to ₹25.6 crores consolidated, demonstrating underlying cash generating strength and resilience of the business model despite margin pressure.
• Profit moderation: Profit for Q1 remained impacted by higher depreciation and interest costs following commissioning of new CAPEX, and profit is expected to remain relatively moderate in FY27 as costs are absorbed ahead of full ramp-up.
• Debt reduction: Management targets paying approximately ₹70 crores of loan repayment, with some LCs converting into term loans, effectively reducing debt by ₹40–50 crores YoY, with ₹40 crores a reasonable assumption.
• Government business shift: Share in government business has declined because the GEM portal has significantly reduced business volumes, and many research institutes have abolished rate contracts and now must use GEM bids for every procurement.
• Glass vs plastics: Management believes the life science industry has clear, non-overlapping markets for glass and plastics, with no cannibalization between the two.

Sehgal: "I personally believe that the life science industry has got a clear market for both glass and plastics. And I don't believe that glass is overlapping into plastic usage and plastic is overlapping into glass usage."

Guidance & Commitments

Key Metrics